GlassScriptPhysician profile
Denis Edward Healey
NPI 1760477343
$8,108.58
in general payments reported to CMS, 2019-2025
44 companies · $818 in 2025
The $818 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $521 · 2021: $1,463 · 2022: $2,083 · 2023: $1,444 · 2024: $840 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,102.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,278.67 | 2021-2025 | Interstim |
| Astellas Pharma US INC | $927.98 | 2019-2025 | Xtandi, Padcev |
| Endo Pharmaceuticals INC. | $533.43 | 2019-2023 | Aveed, Xiaflex, Edex |
| Pfizer INC. | $412.91 | 2019-2025 | |
| Abbvie INC. | $389.06 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $362.59 | 2019-2025 | Provenge |
| Janssen Biotech, INC. | $332.26 | 2019-2025 | Erleada, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $324.52 | 2019-2025 | |
| Coloplast Corp | $309.61 | 2021-2024 | Speedicath |
| Myriad Genetic Laboratories, INC. | $297.55 | 2021-2023 | Prolaris |
| Sumitomo Pharma America, INC. | $278.83 | 2023-2025 | Gemtesa, Orgovyx |
| Urogen Pharma, INC. | $271.30 | 2020-2025 | Jelmyto |
| Amgen INC. | $178.24 | 2019-2024 | Prolia |
| Sn Holdings, LLC | $176.78 | 2022 | |
| Merck Sharp & Dohme LLC | $168.08 | 2022-2024 | Lynparza, Keytruda |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$66,817.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denis Healey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.